期刊文献+

基于非线性混合效应模型的比较药动学分析方法研究 被引量:5

Comparative pharmacokinetic analysis based on nonlinear mixed effect model
原文传递
导出
摘要 比较药动学研究贯穿药物研发的整个阶段,通过求算个体药动学参数,推测各处理因素间AUC、Cmax比值的90%置信区间,然后与事先设定的等效区间进行比较,最终判断各处理因素间是否等效,为用药剂量的合理调整提供依据。然而,很多比较药动学研究为稀疏采样设计,传统的统计矩法很难对个体药动学参数进行估计,此时需要借助群体药动学的计算方法,利用非线性混合效应模型进行计算。本研究在密集采样设计比较药动学研究实例基础之上,模拟稀疏采样过程,对稀疏数据采用非线性混合效应模型分析,原密集数据采用统计矩法分析,通过Bootstrap法1 000次重复抽样,最终比较两种方法所得参数的90%置信区间。结果表明非线性混合效应模型对稀疏数据处理结果可靠,与统计矩法计算结果一致,为此类比较药动学研究提供了参考。 Comparative pharmacokinetic(PK) analysis is often carried out throughout the entire period of drug development,the common approach for the assessment of pharmacokinetics between different treatments requires that the individual PK parameters,which employs estimation of 90% confidence intervals for the ratio of average parameters,such as AUC and Cmax,these 90% confidence intervals then need to be compared with the pre-specified equivalent interval,and last we determine whether the two treatments are equivalent.Unfortunately in many clinical circumstances,some or even all of the individuals can only be sparsely sampled,making the individual evaluation difficult by the conventional non-compartmental analysis.In such cases,nonlinear mixed effect model(NONMEM) could be applied to analyze the sparse data.In this article,we simulated a sparsely sampling design trial based on the dense sampling data from a truly comparative PK study.The sparse data were analyzed with NONMEM method,and the original dense data were analyzed with non-compartment analysis.Although the trial design and analysis methods are different,the 90% confidence intervals for the ratio of PK parameters based on 1000 Bootstrap are very similar,indicated that the analysis based on NONMEM is a reliable method to treat with the sparse data in the comparative pharmacokinetic study.
出处 《药学学报》 CAS CSCD 北大核心 2011年第4期447-453,共7页 Acta Pharmaceutica Sinica
基金 上海市教委重点学科项目(J50303) 上海市高校中医内科E-研究院资助项目(E03008)
关键词 比较药动学 稀疏采样 NONMEM BOOTSTRAP法 comparative pharmacokinetic analysis sparsely sampling NONMEM Bootstrap method
  • 相关文献

参考文献8

  • 1Knebel W, Rao N, Uchimura T, et al. Population pharma- cokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease [J]. J Clin Pharmacol, 2011, 51: 40-52.
  • 2Yoo HD, Cho HY, Lee YB. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic poly- morphisms ofCYP3A5, CYP2C19 and ABCB1 [J]. Br J Clin Pharmacol, 2010, 69: 27-37.
  • 3Dahl SG, Aarons L, Gundert-Remy U, et al. Incorporating physiological and biochemical mechanisms into pharmacoki- netic-pharmacodynamic models: a conceptual framework [J]. Basic Clin Pharmacol Toxicol, 2010, 106: 2-12.
  • 4Reith DM, Hooper WD, Parke J, et al. Population pharma- cokinetic modeling of steady state carbamazepine clearancein children, adolescents and adults [J]. J Pharmacokinet Pharmacodyn, 2001, 28: 79-92.
  • 5Taguchi M, Nozawa T, Igawa A, et al. Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients [J]. Biol Pharm Bull, 2005, 28: 876-881.
  • 6Tatami S, Yamamura N, Sarashina A, et al. Pharmacokinetic comparison of an angiotensin Ⅱ receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method [J]. Drug Metab Pharmacokinet, 2004, 19: 15-23.
  • 7Ide T, Sasaki T, Maeda K, et al. Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic information on SLCO1BI and ABCC2 polymorphisms [J]. J Clin Pharmacol, 2009, 49: 1309-1317.
  • 8Midha KK, MeKay G. Bioequivalence; its history, practice, and future [J]. AAPS J, 2009, 11: 664-670.

同被引文献26

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部